Allarity Therapeutics, Inc. develops personalized cancer treatments as a clinical-stage biopharmaceutical company focused on stenoparib (2X-121), a dual PARP and WNT pathway inhibitor, and its DRP® companion diagnostic technology. The company’s updates center on Phase 2 oncology development, advanced ovarian cancer, clinical and scientific data presentations, companion-diagnostic intellectual property, FDA Fast Track status, and potential use of stenoparib in additional tumor settings.
Recurring news also covers operating and financial results, financing activity that supports clinical programs, research collaborations, and governance matters for the Nasdaq-listed company.
Allarity Therapeutics (NASDAQ: ALLR) said its API manufacturing campaign for stenoparib is on track to finish no later than Q3 2026, supporting an expected pivotal trial in advanced ovarian cancer. The CDMO operates under FDA and EMA GMP standards.
All manufacturing payments are complete and no further manufacturing cash outlays are anticipated, and the campaign aims to align supply with ongoing Phase 2 data generation under an amended protocol.
Allarity Therapeutics (NASDAQ: ALLR) announced a Notice of Allowance from the US Patent and Trademark Office for its Stenoparib DRP® companion diagnostic.
The patent covers multiple claims, including methods to predict benefit from stenoparib using tumor gene expression profiles, is expected to be granted within three months, and would provide exclusivity at least into 2039 when stenoparib is used with the DRP®.
Allarity Therapeutics (NASDAQ: ALLR) presented two posters at AACR Annual Meeting 2026 (April 17–22) highlighting new data on stenoparib (2X-121).
One poster links the stenoparib DRP® to enhanced overall survival in recurrent ovarian cancer; the other shows stenoparib modulates the WNT/β-catenin pathway and inhibits colorectal cancer cell growth at clinically relevant concentrations.
Allarity Therapeutics (NASDAQ: ALLR) reported 2025 results highlighting clinical progress for stenoparib and strengthened finances. Key milestones include FDA Fast Track designation for advanced ovarian cancer, a VA-funded Phase 2 combination trial in SCLC, new Phase 2 ovarian protocol, and a $20 million debt financing extending runway into mid-2028.
Financials: year-end cash of $14.7M, revenue of $0.32M, R&D $6.6M, G&A $6.3M, and net loss of $11.2M for 2025.
Allarity Therapeutics (NASDAQ: ALLR) closed a $20.0 million non-convertible debt financing with Streeterville Capital on March 6, 2026.
The financing, structured as two promissory notes (one secured), is expected to extend cash runway into mid-2028 and fund completion of the Phase 2 ovarian cancer trial, FDA meeting preparation, companion diagnostic work, and pivotal trial readiness.
Allarity Therapeutics (NASDAQ: ALLR) announced dosing of the first patients in a VA-funded investigator-initiated Phase 2 trial evaluating stenoparib plus temozolomide for relapsed small cell lung cancer (SCLC) on February 18, 2026. The trial is open at 11 VA sites and fully funded by the U.S. Department of Veterans Affairs.
Stenoparib is a dual PARP and WNT pathway inhibitor with reported blood-brain barrier penetration; the combination aims to enhance temozolomide efficacy while potentially reducing toxicity seen with earlier PARP inhibitors.
Allarity Therapeutics (NASDAQ: ALLR) announced a VA-funded Phase 2 trial combining stenoparib with temozolomide in relapsed small cell lung cancer (SCLC), now open for enrollment at 11 VA sites across the US as of February 3, 2026. The study (NCT06681220) will assess safety and efficacy and uses a blood-based biomarker to select patients.
The trial tests stenoparib’s dual PARP/WNT inhibition and aims to improve tolerability versus prior PARP+temozolomide combinations while exploring activity against brain metastases.
Allarity Therapeutics (NASDAQ: ALLR) CEO letter dated December 31, 2025 reviews two years of strategic refocus and execution centered on stenoparib (2X-121), a dual PARP/WNT inhibitor for advanced ovarian cancer and other difficult cancers.
Key developments: FDA Fast Track designation for stenoparib; updated AACR data showing median overall survival not reached with median follow-up >22 months; two patients on therapy >30 months; a new Phase 2 protocol; a VA-funded recurrent small cell lung cancer trial; a DRP licensing and lab services agreement; simplified capital structure and restored Nasdaq compliance; selective share repurchases and a cash runway aligned with development goals.
Allarity Therapeutics (NASDAQ: ALLR) reported Q3 2025 results and operational updates on November 14, 2025. Key clinical progress includes FDA Fast Track designation for stenoparib in advanced ovarian cancer and Phase 2 data showing median overall survival now exceeding 25 months. The company signed a commercial license for selected DRP® breast cancer algorithms and maintains an IBRI research collaboration to study stenoparib’s dual PARP/WNT mechanism. Financially, Allarity ended Q3 with $16.9 million cash (down $0.9M QoQ) and a reported net loss of $2.8 million. The company expects a VA-funded SCLC combination trial to open by year-end 2025 and projects a financial runway through December 2026.
Allarity Therapeutics (NASDAQ: ALLR) has presented groundbreaking Phase 2 clinical data for stenoparib/2X-121 at the AACR Special Conference on Ovarian Cancer. The trial's Kaplan-Meier analyses revealed that median Overall Survival (mOS) has exceeded 25 months in platinum-resistant and refractory ovarian cancer patients.
Key highlights include two patients continuing therapy beyond 24 months, including one with wild-type BRCA gene. The drug shows clinical benefits regardless of BRCA status, distinguishing it from first-generation PARP inhibitors. Notably, stenoparib's mOS of >25 months significantly outperforms recent FDA-approved therapies' mOS of 16-16.5 months for platinum-resistant ovarian cancer (PROC) patients.
The drug demonstrates a favorable safety profile with reduced myelotoxicity compared to earlier PARP inhibitors, and its dual inhibition of PARP1/2 and WNT pathway shows promise for broader patient benefit.